MarketScreener Strategies Genome & Company

Equities

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-07-16 pm EDT			5-day change	1st Jan Change
9,640 ^KRW	+15.73%		+13.41%	-22.82%

Jan. 24	Genome & Company Announces Positive Topline Results from Phase 2 Clinical Trial of Combination of GEN-001 and Bavencio®? for the Treatment of Gastric Cancer Poster Presented at ASCO GI	CI
2023	Genome & Company Announces Positive Results from Interim Analysis of Gen-001 Plus Avelumab (Bavencio®?) Phase II Trial	CI

No results for this search